Federman & Sherwood Investigates Mattson Technology, Inc. (“Mattson”) for Data Breach
Federman & Sherwood Investigates Mattson Technology, Inc. (“Mattson”) for Data Breach
Federman & Sherwood investigates Mattson Technology, Inc. (“Mattson”) for data breach. Mattson became aware of a cybersecurity incident on April 30, 2023. Mattson launched an investigation into the incident and determined that between April 11, 2023, and April 29, 2023, an unauthorized actor accessed and/or removed files from their network. Some of those files contained personal and sensitive information of certain individuals. Mattson designs, manufactures, markets and globally supports semiconductor wafer processing equipment used in the fabrication of integrated circuits
The type of information potentially exposed includes:
- Full Name
- Social Security Number
- Other sensitive information
If you wish to discuss this action, obtain further information, and/or participate in this litigation, please contact Tiffany Peintner either by email at trp@federmanlaw.com or visit our firm’s website www.federmanlaw.com.
Tiffany Peintner
FEDERMAN & SHERWOOD
(405) 235-1560
View source version on businesswire.com: https://www.businesswire.com/news/home/20240927902870/en/
-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks